Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT.
Mahbubl AhmedChee GohEdward SaundersClara Cieza-Borrellanull nullZsofia Kote-JaraiFredrick R SchumacherRosalind A EelesPublished in: Prostate cancer and prostatic diseases (2019)
Men with a higher polygenic risk score are more likely to develop prostate cancer. There were no interactions of these germline risk SNPs and the chemoprevention agents in the SELECT and PCPT trials.